Effect of PPAR-gamma agonist on aerobic exercise capacity in relation to body fat distribution in men with type 2 diabetes and coronary artery disease.

CONCLUSIONS: Treatment with the insulin sensitizer PPAR-gamma agonist rosiglitazone in patients with T2DM and CAD is associated with a worsening in exercise capacity, which seems to be mainly attributable to weight gain and subcutaneous fat mass expansion. PMID: 30964707 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30964707?dopt=Abstract

Source: American Journal of Physiology. Endocrinology and Metabolism - April 8, 2019 Category: Physiology Authors: Bastien M, Poirier P, Brassard P, Arsenault BJ, Bertrand OF, Després JP, Costerousse O, Piche ME Tags: Am J Physiol Endocrinol Metab Source Type: research